The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Experience with 177Lu-Dotatate in patients with metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NET): Report from a single urban cancer center.
 
Aria Kieft
No Relationships to Disclose
 
Yahya Ibrahim
No Relationships to Disclose
 
Gregory Dyson
No Relationships to Disclose
 
Geoffrey Baran
No Relationships to Disclose
 
Asfar S. Azmi
No Relationships to Disclose
 
Mohammed Najeeb Al Hallak
Speakers' Bureau - Ipsen
 
Anthony Frank Shields
Consulting or Advisory Role - Caris Life Sciences; ImaginAb
Speakers' Bureau - Caris Life Sciences
Research Funding - Alkermes; Astellas Pharma; AstraZeneca; Bayer; Boehringer Ingelheim; Boston Biomedical; Caris Life Sciences; Daiichi Sankyo; Eisai; Esperas Pharma; Esperas Pharma; Exelixis; Five Prime Therapeutics; H3 Biomedicine; Halozyme; Hutchison China Meditech; ImaginAb; Incyte; Inovio Pharmaceuticals; Jiangsu Alphamab Biopharmaceuticals; Lexicon; LSK BioPharma; MSK Pharma; Nouscom; Plexxikon; Repertoire Immune Medicines; Seagen; Shanghai HaiHe Pharmaceutical; Taiho Pharmaceutical; Telix Pharmaceuticals; TopAlliance BioSciences Inc (Inst); Xencor
Travel, Accommodations, Expenses - Caris Life Sciences; GE Healthcare; ImaginAb; Inovio Pharmaceuticals; TransTarget
 
Nitin Vaishampayan
No Relationships to Disclose
 
Philip Agop Philip
Honoraria - Array BioPharma; AstraZeneca; Bayer; Blueprint Medicines; Celgene; Ipsen; Merck; SynCoreBio; TriSalus Life Sciences
Consulting or Advisory Role - Celgene; Daiichi Sankyo; Ipsen; Merck; SynCoreBio; Taiho Pharmaceutical; TriSalus Life Sciences
Speakers' Bureau - Bayer; Celgene; Incyte; Ipsen; Novartis
Research Funding - Advanced Accelerator Applications (Inst); ASLAN Pharmaceuticals (Inst); Bayer (Inst); boston biomedical (Inst); Caris Life Sciences (Inst); Caris Life Sciences (Inst); Genentech (Inst); halozyme (Inst); Immunomedics (Inst); incyte (Inst); incyte (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Merck (Inst); merus (Inst); Momenta Pharmaceuticals (Inst); novartis (Inst); Plexxikon (Inst); QED Therapeutics (Inst); QED Therapeutics (Inst); Regeneron (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); TYME (Inst); tyme (Inst)
Travel, Accommodations, Expenses - Abbvie; celgene; Rafael Pharmaceuticals
(OPTIONAL) Uncompensated Relationships - Caris MPI; Rafael Pharmaceuticals